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Rice et al General Thoracic Surgeryvalue, particularly in asymptomatic patients (ie, those not
taking anti-reflux medication). Rather, endoscopy should
be directed toward detection of cancer recurrence and diag-
nosis of symptoms.G
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Discussion
Dr Farzaneh Banki (Houston, Tex). I thank Drs Milliken and
Bremner for the opportunity to discuss this article and congratulate
Dr Rice and colleagues on providing the largest series with long-term
follow-up that elucidates the fate of gastroesophageal anastomosis
and mucosal changes in esophageal remnant after esophagectomy.
This study has multiple clinical implications, including the need
for surveillance and use of proton-pump inhibitor after esophagec-
tomy, and once again proves that cardiac mucosa is an acquired
metaplastic epithelium that arises from squamous mucosa in re-
sponse to gastric acid. I have 3 questions.
In your study, the curve for development of cardiac mucosa is
biphasic, so there is an early and a late development of cardiac mu-
cosa, but the development of intestinal metaplasia is linear and in-
creases with time. Although one can explain the early development
of cardiac mucosa by acute exposure of the esophageal remnant to
acid and bile, and the late development by chronic exposure and by
the fact that despite vagotomy the stomach regains its capacity to
produce acid with time, how do you explain the decline between
2.5 and 4.5 years in development of cardiac mucosa in your study?The Journal of Thoracic and CaDr Rice. I think it is explained by sampling error. If you don’t
biopsy the columnar mucosa, you are not going to find it. We tried
to do another analysis on reaching the greatest change, but that be-
came very confusing to present.
Dr Banki. Prior studies with a small number of patients have
shown that presence of intestinal metaplasia in the esophagus be-
fore esophagectomy is an important predictive factor for develop-
ment of intestinal metaplasia in esophageal remnant after
esophagectomy. Have you considered that as a factor in your mul-
tivariate analysis?
DrRice. That variable was not considered. We hope that benign
versus malignant indication would be a surrogate. I would remind
you that the studies on intestinal metaplasia, and it is a variable fac-
tor (yes in some studies and no in others), were done mostly in pa-
tients with low intrathoracic anastomosis, and we have no idea
about the surgical margin. Indeed, if you don’t take out the Bar-
rett’s and you do your first biopsy, you are going to find Barrett’s
because your operation was incomplete—another reason to go
high in the neck. But you are absolutely right, we should probably
add to our analysis the presence of Barrett’s mucosa before the
esophagectomy.
Dr Banki. Have you changed your yearly surveillance protocol
for endoscopy and routine biopsies and the use of proton-pump
inhibitors in your patients after esophagectomy as a result of this
article?
Dr Rice. I still use proton-pump inhibitors for symptoms, but I
have a low tolerance to use them. Of course we are going to do our
surveillance for cancer recurrence, but I think surveillance for can-
cer progression is probably not wise. Maybe if you are going to do
it every 5 years, it may be a good way to check for progression of
Barrett’s at the anastomosis.
Dr Ross Bremner (Phoenix, Ariz). Tom, have you considered
doing an anti-reflux procedure? Glyn Jamieson and his group in
Australia just published some compelling data on a prospective
study they did with a high intrathoracic anti-reflux procedure
that showed no difference in dysphagia but a remarkable differ-
ence in reflux. Is that something you would consider doing?
DrRice.Doyoumean a fundoplication about a low anastomosis?
Dr Bremner. Actually just do an anti-reflux high up in the
chest.
DrRice. I try to use full gastric tube, full gastric remnant, when-
ever I can, but usually there is not enough stomach in the neck to do
that anti-reflux procedure.
Dr Steve Demeester (Los Angeles, Calif). Tom, those are nice
data, important data. What was the longest length of columnar mu-
cosa that you saw develop over time in these patients?
Dr Rice.We did not rely on the measurement of columnar mu-
cosa. Most of the columnar mucosa we found was on histopatho-
logic biopsy, but we did see a few cases endoscopically of
approximately 1 cm.
Dr Demeester. So most of the time the anastomosis appeared
relatively normal.
Dr Rice. Yes, to my eye it appeared relatively normal and the
reflux changes were histopathologic, and surprisingly, a number
were ulcerative when things looked reasonably okay.
Dr Demeester. Good, and then just a follow-up question on
that. In light of this, the Cleveland Clinic, in particular John (Gold-
blum), has been a big proponent that all cardiac mucosa intestinalrdiovascular Surgery c Volume 141, Number 4 879
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Smetaplasia at the gastroesophageal junction in its normal location
is a Helicobacter pylori–related phenomenon. Has this altered his
thinking at all seeing these data?
Dr Demeester.You will have to talk to John, but we discuss this
frequently. His belief is that the cardia mucosa in its normal posi-
tion at the esophagogastric junction, which of course we excise880 The Journal of Thoracic and Cardiovascular Surgduring this operation, is normal mucosa, and when we find it any-
where else it is metaplastic. Certainly with some of the findings we
observed, it is hard to tell where the columnar mucosa was at that
anastomosis, but one could believe that some of it was on the gas-
tric side of the anastomosis. So we are learning about the esopha-
gogastric junction and the esophagogastric anastomosis.ery c April 2011
